表紙
市場調查報告書

免疫抑制劑的全球市場的未來預測 (2019∼2028年)

Global Immunosuppressant Drugs Market Forecast 2019-2028

出版商 Inkwood Research 商品編碼 939709
出版日期 內容資訊 英文 135 Pages
商品交期: 2-3個工作天內
價格
免疫抑制劑的全球市場的未來預測 (2019∼2028年) Global Immunosuppressant Drugs Market Forecast 2019-2028
出版日期: 2020年06月01日內容資訊: 英文 135 Pages
簡介

全球免疫抑制劑市場在2019∼2028年間,預測將以4.17%的年複合成長率成長。市場成長的主要因素有自體免疫疾病的發生率上升,及製藥產業的成長,器官移植的數量增加等。

本報告提供全球免疫抑制劑的市場相關分析,市場基本結構和主要的促進、阻礙因素,市場規模趨勢預測 (今後10年份),各流通管道、各終端用戶、各類藥物及各地區詳細趨勢,市場競爭趨勢,主要企業的簡介 (企業概要,主要產品/服務,事業策略等) 等相關調查。

第1章 調查範圍、手法

第2章 摘要整理

第3章 市場動態

  • 免疫抑製藥的開發情形
  • 市場定義
  • 主要的推動市場要素
    • 自體免疫疾病的患者數增加
    • 器官移植的普及
    • 製藥產業的成長
  • 主要的阻礙市場要素
    • 免疫抑製藥的副作用
    • 內臟器官提供相關意識的缺乏

第4章 主要分析

  • 主要投資考察
  • 波特的五力分析
  • 市場機會矩陣
  • 業者情勢

第5章 各流通管道的市場

  • 醫院藥局
  • 零售藥局
  • 線上藥局

第6章 各終端用戶的市場

  • 器官移植
  • 自體免疫疾病
  • 其他

第7章 各類藥物市場

  • 皮質類固醇
  • 單株抗體
  • Calcineurin抑制劑
  • mTOR抑制劑
  • 其他

第8章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他歐洲各國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 越南
    • 澳洲、紐西蘭
    • 其他的亞太地區各國
  • 其他的國家 (RoW)
    • 南美
    • 中東、非洲

第9章 企業簡介

  • ABBVIE INC
  • ALLERGAN PLC (由ABVIE INC收購)
  • ASTELLAS PHARMA INC
  • BRISTOL-MYERS SQUIBB COMPANY
  • CIPLA LTD
  • DR. REDDY'S LABORATORIES LTD
  • F HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • MYLAN NV
  • NOVARTIS INTERNATIONAL AG (SANDOZ)
  • PFIZER INC
  • SANOFI SA
  • VELOXIS PHARMACEUTICALS
目錄
Product Code: 31808

KEY FINDINGS

The global immunosuppressant drugs market is projected to register growth at a CAGR of 4.17% during the projected period, 2019-2028. The growing incidences of autoimmune disorders, the growing pharmaceutical industry, and the increase in organ transplantation, are the major factors fueling the market growth.

MARKET INSIGHTS

Organ transplantation has been on the rise across the globe. This is because of the prevalence of genetic conditions like cystic fibrosis, heart defect, and polycystic kidney disease. Infections like hepatitis, damage to organs due to chronic conditions like diabetes, physical injuries, are other factors that are responsible for an organ transplant. Immunosuppressive drugs come into the scene post organ transplantation, while combatting the hyper-immune response of the patient's immune system. Thus, the growing demand for organ transplantation procedures is estimated to have a major impact on the growth of the market. Though immunosuppressive drugs have improved the outcome of organ transplantation, the side effects of such drugs can be serious, and this is one of the major factors hindering the market growth.

REGIONAL INSIGHTS

The global immunosuppressant drugs market is geographically analyzed through the regions of Europe, North America, Asia Pacific, and the rest of the world. The North America region garnered the largest market share, while the Asia Pacific region is slated to record the highest growth rate by the end of the forecast period. The government funding, prevailing auto-immune diseases, and increasing demands for organ transplantation, contribute to the market prospects of North America.

COMPETITIVE INSIGHTS

The competitive environment of the market is evaluated to be stiff, given the workings of the pharmaceutical business. Some of the leading companies in the market are Allergan Plc (Acquired By AbbVie Inc), Bristol-Myers Squibb Company, Cipla Ltd, AbbVie Inc, Astellas Pharma Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
    • 3.3.2. RISE IN ORGAN TRANSPLANTATION
    • 3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
  • 3.4. KEY RESTRAINTS
    • 3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
    • 3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL

  • 5.1. HOSPITAL PHARMACIES
  • 5.2. RETAIL PHARMACIES
  • 5.3. ONLINE PHARMACIES

6. MARKET BY END-USER

  • 6.1. ORGAN TRANSPLANTATION
  • 6.2. AUTOIMMUNE DISORDERS
  • 6.3. OTHERS

7. MARKET BY DRUG CLASS

  • 7.1. CORTICOSTEROIDS
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. CALCINEURIN INHIBITORS
  • 7.4. MTOR INHIBITORS
  • 7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UNITED KINGDOM
    • 8.2.2. GERMANY
    • 8.2.3. FRANCE
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. SOUTH KOREA
    • 8.3.5. INDONESIA
    • 8.3.6. THAILAND
    • 8.3.7. VIETNAM
    • 8.3.8. AUSTRALIA & NEW ZEALAND
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. ABBVIE INC
  • 9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
  • 9.3. ASTELLAS PHARMA INC
  • 9.4. BRISTOL-MYERS SQUIBB COMPANY
  • 9.5. CIPLA LTD
  • 9.6. DR. REDDY'S LABORATORIES LTD
  • 9.7. F HOFFMANN-LA ROCHE AG
  • 9.8. GLAXOSMITHKLINE PLC
  • 9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • 9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • 9.11. MYLAN NV
  • 9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
  • 9.13. PFIZER INC
  • 9.14. SANOFI SA
  • 9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
  • TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
  • TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
  • TABLE 4: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL ORGAN TRANSPLANTATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL ORGAN TRANSPLANTATION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL CALCINEURIN INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL CALCINEURIN INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 34: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 36: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 38: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 40: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
  • FIGURE 7: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
  • FIGURE 11: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
  • FIGURE 15: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 24: UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: GERMANY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: FRANCE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: ITALY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: BELGIUM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 30: POLAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: REST OF EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 33: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 37: INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: THAILAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 40: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: REST OF ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION
  • FIGURE 42: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 43: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 44: MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)